BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy

Previous
Previous

China's Biotech Financing Was Already Changing. What Will COINS Add?

Next
Next

From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?